Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.720
+0.030 (0.64%)
Jul 11, 2025, 4:08 PM HKT

Jacobio Pharmaceuticals Group Company Description

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies.

Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under multiple stage studies for indications such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications including NSCLC, PDAC, CRC, and other solid tumors; JAV-8263, a BET inhibitor for solid and liquid tumors; JAB-2485 Aurora A inhibitor, JAB-30355 P53 Y220C inhibitor, JAB-BX102 CD73 mAb inhibitor, JAB-26766 PARP 7 inhibitor, and JAB-BX300 LIF inhibitor under trials for solid tumor indications; and JAB-24114, a glutamine-utilizing enzyme for solid tumor and hematological malignancy indications.

The company also develops IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications.

It has a collaboration agreement with Merck for cetuximab for combination trials. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.

Jacobio Pharmaceuticals Group Co., Ltd.
Country Cayman Islands
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 257
CEO Yinxiang Wang

Contact Details

Address:
Building 8
Beijing
China
Website jacobiopharma.com

Stock Details

Ticker Symbol 1167
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number KYG4987A1094
SIC Code 2836

Key Executives

Name Position
Dr. Yinxiang Wang Executive Chairman and Chief Executive Officer
Xiaojie Wang Executive Director and President of Administration
Yunyan Hu Executive Vice President and Executive Director
Tao Yang Vice President of Human Resources
Dr. Andrea Wang-Gillam M.D., Ph.D. Executive Vice President, Chief Medical Officer and Global Head of Research & Development
Yanping Wang Executive Vice President of Non-Clinical Research & Development
Dr. Haijun Wang Senior Vice President of Information and Data Management
Yuli Ding Executive Vice President of Clinical Development
Qing Xue Joint Company Secretary
Ming Fai Chung CPA Joint Company Secretary